343 related articles for article (PubMed ID: 15865827)
1. Infection by the respiratory syncytial virus in infants and young children at high risk.
Bonnet D; Schmaltz AA; Feltes TF
Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
3. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
Tulloh RM; Feltes TF
Cardiol Young; 2005 Jun; 15(3):274-8. PubMed ID: 15865829
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
Pin I; Pilenko C; Bost M
Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
[TBL] [Abstract][Full Text] [Related]
8. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
9. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
10. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
Chantepie A;
Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
[TBL] [Abstract][Full Text] [Related]
11. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
Cabalka AK
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
Tulloh R; Marsh M; Blackburn M; Casey F; Lenney W; Weller P; Keeton BR;
Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
[TBL] [Abstract][Full Text] [Related]
13. [Respiratory syncytial virus infections and preventive options].
Rothbarth PH; Kimpen JL; Roord JJ; Neijens HJ
Ned Tijdschr Geneeskd; 2000 Jan; 144(1):15-9. PubMed ID: 10665299
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
15. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
16. Prevention of respiratory syncytial virus infection in high risk infants.
Prince AM; Jacobs RF
J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
[TBL] [Abstract][Full Text] [Related]
17. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
18. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Cardenas S; Auais A; Piedimonte G
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
20. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
